Oslo, 25 May 2023. Lytix Biopharma - Lytix Biopharma AS ("Lytix") (Euronext
Growth Oslo: LYTIX), a Norwegian immuno-oncology company - is pleased to
announce that Dr Øystein Rekdal, CEO in Lytix Biopharma, will be presenting the
company at two events in Stockholm next week. 

o	The ABG Sundal Collier Life Science Summit, Wednesday 31 May at 11:30 CET  
o	Redeye Growth Day 2023, Thursday 1 June at 12:55 CET

A prerecorded Lytix presentation for Redeye Growth Day is available at
https://www.redeye.se/video/company-prerecorded-presentation/911051/lytix-biopha
rma


For more information, please contact: 
Ole Peter Nordby, Head of IR: ole.peter.nordby@lytixbiopharma.com


Lytix Biopharma in brief
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immune-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class oncolytic molecule representing a new
and superior in situ therapeutic vaccination principle to boost anti-cancer
immunity, with the potential to be the ideal combination partner with other
types of immunotherapies. LTX-315 target cancer cells and disintegrate their
cell membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens.  This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors such as
PBM Capital, a US based, healthcare-focused investment firm.